Last reviewed · How we verify

NCT05341037

Red Cell Distribution With to Lymphocyte Ratio in Cardiac Surgery

Completed Last updated 8 August 2022
What this trial tests

trial in Cardiac Surgery in 700 participants. Completed in 1 August 2022.

Timeline
15 June 2022
Primary endpoint
1 July 2022
1 August 2022

Quick facts

Lead sponsorAnkara City Hospital Bilkent
StatusCompleted
Study typeOBSERVATIONAL
Enrollment700
Start date15 June 2022
Primary completion1 July 2022
Estimated completion1 August 2022
Sites1 location across Turkey (Türkiye)

Conditions studied

Sponsor

Ankara City Hospital Bilkent

Who can join

18 and older, any sex, with Cardiac Surgery. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

It is aimed to investigate whether red cell distribution with (RDW) to lymphocyte ratio (RLR) can predict early comorbidity among cardiac surgery patients.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. A new hematologic predictor of major adverse events after cardiac surgery: red cell distribution width to lymphocyte ratio.
    Kurtbeyoğlu S, Demir A, Balcı E, Özay HY, et al · · 2023 · PMID 37468199 · DOI 10.17085/apm.22244

Verify or expand the search:

Other recruiting trials for Cardiac Surgery

Currently open trials in the same condition.

Other Ankara City Hospital Bilkent trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05341037.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing